Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.
The IDH1 inhibitor is the third medication approved this year for hard-to-treat bile duct cancer.
New targeted therapy shrank tumors in nearly a quarter of patients with bile duct cancer.
COVID-19, FDA drug approvals and new approaches to treatment and quality of life stood out among this year’s top stories.
Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.
Over a third of bile duct cancer patients treated with the kinase inhibitor experienced complete or partial tumor remission.
TRK inhibitor larotrectinib led to durable responses in people with colon, pancreatic, appendix, bile duct and liver cancers.
IDH1 inhibitor delayed progression of this often aggressive cancer of the bile ducts.
Hilary Saltzman is a cholangiocarcinoma cancer survivor who lives in Austin with her husband and two children.
A new systematic review and meta-analysis indicates that hepatitis C is most notably also associated with B-cell non–Hodgkin lymphoma.
To improve quality of life, drug development researchers are bringing patients into the process at the beginning
A cancer diagnosis often means extreme financial stress—and fights with insurance providers.
The “LazyTown” actor had bile duct cancer.
Know you are not alone. Many others have had your experience, including me.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.